Terms: = Lymphoma AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
536 results:
1. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
2. Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-il2 bispecific immunotoxin in rats and minipigs.
Wang Z; Ramakrishna R; Wang Y; Qiu Y; Ma J; Mintzlaff D; Zhang H; Li B; Hammell B; Lucia MS; Pomfret E; Su AA; Washington KM; Mathes DW; Wang Z
Eur J Pharmacol; 2024 Apr; 968():176408. PubMed ID: 38367684
[TBL] [Abstract] [Full Text] [Related]
3. Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-lymphoma.
Nakashima M; Tanaka Y; Okamura H; Kato T; Imaizumi Y; Nagai K; Miyazaki Y; Murota H
Cells; 2024 Jan; 13(2):. PubMed ID: 38247820
[TBL] [Abstract] [Full Text] [Related]
4. Higher Expression of Human Endogenous Retrovirus-K was Observed in Peripheral B Lymphocytes of Leukemia and lymphoma Patients.
Li T; Qian K; Han J; Liu Y; Jia L; Wang X; Li T; Zhang B; Li J; Li H; Dou L; Li L
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):268-279. PubMed ID: 38009220
[TBL] [Abstract] [Full Text] [Related]
5. Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
Ji Q; Wu X; Zhang Y; Zeng L; Dong Y; Liu R; Li B; Bai Z; Hu S; Lu J; Wu S
Eur J Haematol; 2024 Jan; 112(1):75-82. PubMed ID: 37649264
[TBL] [Abstract] [Full Text] [Related]
6. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes.
Bao C; Gu J; Huang X; You L; Zhou Z; Jin J
Cytokine; 2023 Sep; 169():156289. PubMed ID: 37453327
[TBL] [Abstract] [Full Text] [Related]
7. The genetic polymorphisms of immune-related genes contribute to the susceptibility and survival of lymphoma.
Gu C; Can C; Liu J; Wei Y; Yang X; Guo X; Wang R; Jia W; Liu W; Ma D
Cancer Med; 2023 Jul; 12(14):14960-14978. PubMed ID: 37329186
[TBL] [Abstract] [Full Text] [Related]
8. Diagnostic and management roles of FDG PET/CT imaging in post-transplant lympho-proliferation in pediatric heart transplantation.
Brown AK; Carapellucci J; Oshrine B; Gomez A; Meoded A; Asante-Korang A
Clin Transplant; 2023 Sep; 37(9):e15015. PubMed ID: 37237443
[TBL] [Abstract] [Full Text] [Related]
9. Case report of extranodal natural killer/T-cell lymphoma that induced secondary hemophagocytic syndrome-related histiocytic glomerulopathy.
Xiao F; Hou S; Kui K; Wang X; Bai L; Dai H
J Int Med Res; 2023 May; 51(5):3000605231158952. PubMed ID: 37161317
[TBL] [Abstract] [Full Text] [Related]
10. [Adult T-cell leukemia/lymphoma with multiple intracranial masses and CMV and HHV-6 reactivation at initial presentation].
Hori T; Yasui S; Hosoki M; Yamagami H; Otoda T; Yuasa T; Aihara KI; Takishita M; Abe M; Nakamura S
Rinsho Ketsueki; 2023; 64(4):283-289. PubMed ID: 37121773
[TBL] [Abstract] [Full Text] [Related]
11. External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center.
Li A; De Las Pozas G; Andersen CR; Nze CC; Toale KM; Milner EM; Fillmore NR; Chiao EY; Rojas Hernandez C; Kroll MH; Merriman KW; Flowers CR
Am J Hematol; 2023 Jul; 98(7):1052-1057. PubMed ID: 37067102
[TBL] [Abstract] [Full Text] [Related]
12. ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas.
Jiang B; Weinstock DM; Donovan KA; Sun HW; Wolfe A; Amaka S; Donaldson NL; Wu G; Jiang Y; Wilcox RA; Fischer ES; Gray NS; Wu W
Cell Chem Biol; 2023 Apr; 30(4):383-393.e6. PubMed ID: 37015223
[TBL] [Abstract] [Full Text] [Related]
13. Identification of Hub Genes Associated with Resistance to Prednisolone in Acute Lymphoblastic Leukemia Based on Weighted Gene Co-expression Network Analysis.
Nekoeian S; Ferdowsian S; Asgari Y; Azizi Z
Mol Biotechnol; 2023 Nov; 65(11):1913-1922. PubMed ID: 36877306
[TBL] [Abstract] [Full Text] [Related]
14. Phase I Study: Safety and Efficacy of an Ex Vivo-Expanded Allogeneic Natural Killer Cell (MG4101) with Rituximab for Relapsed/Refractory B Cell Non-Hodgkin lymphoma.
Yoon DH; Koh Y; Jung M; Kwak JE; Shin EC; Hwang YK; Kim WS
Transplant Cell Ther; 2023 Apr; 29(4):253.e1-253.e9. PubMed ID: 36610490
[TBL] [Abstract] [Full Text] [Related]
15. Potent immunomodulatory and antitumor effect of anti-CD20-il2no-alpha tri-functional immunocytokine for cancer therapy.
Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
[TBL] [Abstract] [Full Text] [Related]
16. A split, conditionally active mimetic of il-2 reduces the toxicity of systemic cytokine therapy.
Quijano-Rubio A; Bhuiyan AM; Yang H; Leung I; Bello E; Ali LR; Zhangxu K; Perkins J; Chun JH; Wang W; Lajoie MJ; Ravichandran R; Kuo YH; Dougan SK; Riddell SR; Spangler JB; Dougan M; Silva DA; Baker D
Nat Biotechnol; 2023 Apr; 41(4):532-540. PubMed ID: 36316485
[TBL] [Abstract] [Full Text] [Related]
17. IL-7: Comprehensive review.
Winer H; Rodrigues GOL; Hixon JA; Aiello FB; Hsu TC; Wachter BT; Li W; Durum SK
Cytokine; 2022 Dec; 160():156049. PubMed ID: 36201890
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of Short-Term Efficacy of PD-1 Monoclonal Antibody Immunotherapy for lymphoma by Positron Emission Tomography/Computed Tomography Imaging with Convolutional Neural Network Image Registration Algorithm.
Fang J; Chen Z
Contrast Media Mol Imaging; 2022; 2022():1388517. PubMed ID: 36105450
[TBL] [Abstract] [Full Text] [Related]
19. il-2/il-2R signaling and il-2Rα-targeted therapy in anaplastic large cell lymphoma.
Liang HC
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):25-30. PubMed ID: 36094651
[TBL] [Abstract] [Full Text] [Related]
20. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
Front Immunol; 2022; 13():907673. PubMed ID: 35677056
[TBL] [Abstract] [Full Text] [Related]
[Next]
